Comparative Pharmacology
Head-to-head clinical analysis: CHOLEDYL SA versus THEOCLEAR 200.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLEDYL SA versus THEOCLEAR 200.
CHOLEDYL SA vs THEOCLEAR-200
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Choledyl SA (theophylline, sustained-release) is a methylxanthine that inhibits phosphodiesterase, increasing intracellular cAMP, and blocks adenosine receptors, leading to bronchodilation and anti-inflammatory effects.
Theophylline is a methylxanthine that inhibits phosphodiesterase, increasing intracellular cAMP levels, leading to bronchodilation. It also acts as an adenosine receptor antagonist and may enhance diaphragmatic contractility.
400 mg orally every 12 hours (sustained-release); maximum 800 mg every 12 hours.
Theophylline 200 mg orally every 6 hours (extended-release) or as directed by serum theophylline concentrations. Usual adult target: 400-600 mg/day.
None Documented
None Documented
Terminal elimination half-life: 7-9 hours in healthy adults; prolonged in hepatic cirrhosis (up to 30 hours), heart failure, COPD, and in neonates; shortened in smokers and cystic fibrosis.
Terminal elimination half-life: ~8 hours (range 3–12 hours) in adults; prolonged in hepatic impairment, heart failure, COPD, and neonates. Significantly shorter in smokers (4–6 hours).
Renal: 90% as unchanged drug and metabolites (theophylline metabolites including 1,3-dimethyluric acid, 3-methylxanthine, and 1-methyluric acid). Biliary/fecal: <10%.
Renal: ~10% unchanged; Hepatic metabolism (CYP1A2, CYP3A4) accounts for ~90% of elimination; metabolites (caffeine, 3-methylxanthine, 1-methyluric acid) excreted renally. Fecal excretion negligible.
Category C
Category C
Bronchodilator
Bronchodilator